Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Fesoterodine for the treatment of urinary incontinence and overactive bladder
Therapeutics and Clinical Risk Management, 11/04/09
Ellsworth P – Fesoterodine is one of the newest antimuscarinic agent approved for the management of OAB. It is unique in that it shares the same active metabolite as tolterodine, 5–hydoxymethyltolterodine (5–HMT); however, this conversion is established via ubiquitous esterases and not via the cytochrome P450 system, thus providing a faster and more efficient conversion to 5–HMT. Fesoterodine is available in 2 doses, 4 mg and 8 mg. Clinical trials have established a dose response relationship in efficacy parameters as well as improvements in quality of life. As with all antimuscarinics, dry mouth and constipation are the more common side effects. A combination of medical therapy and behavioral therapy improves the overall outcome in management of OAB. Dose flexibility may help improve efficacy outcomes and patient education on the management of common adverse effects may improve tolerability with these agents.
Related Articles
Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity
BJU International, 11/11/09
Relevance Score: 82%
Fesoterodine: a new antimuscarinic for overactive bladder
Aging Health, 10/13/09
Relevance Score: 79%
Prevalence and Severity of Undiagnosed Urinary Incontinence in Women
American Journal of Medicine, 10/27/09
Relevance Score: 71%
Etiology and predictors of urinary incontinence and its effect on quality of life
Geriatrics and Gerontology International, 11/17/09
Relevance Score: 70%
Urinary Incontinence Therapy Area Pipeline Report
Internet Source, 10/30/09
Relevance Score: 70%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Annals of Oncology, 11/24/09
Effect of Chronic Sildenafil Treatment on Penile Endothelial Function: A Randomized, Double-Blind, Placebo Controlled Study
The Journal of Urology, 11/24/09
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
The Journal of Urology, 11/23/09
Today in Voiding Dys/Incontinence...keeping you current
Receive free subspecialty "5-minute updates" via email
Prospective Study of Transcutaneous Parasacral Electrical Stimulation for Overactive Bladder in Children: Long-Term Results
The Journal of Urology, 11/24/09
Risk Factors for Nocturnal Enuresis in School-Age Children
The Journal of Urology, 11/24/09
Differences and associations between nocturnal voiding/nocturia and sleep disorders
BJU International, 11/24/09
Article Search
Sponsor


See Latest Articles


